title: Results of a user satisfaction study carried out in women using Uniplant contraceptive implant.
abstract: A study of the acceptability of Uniplant, a 12-month single implant of nomegestrol acetate, included 819 women from Africa, Latin America, and China, participating in a clinical trial of Uniplant. A standard, pre-coded questionnaire was specially designed for this purpose and applied at the moment of removal of implant, either at the end of 12 months of use or at the time of discontinuation for whatever reason. The level of satisfaction proved high when users' comparison with their previous contraceptive method, users' recommendation of Uniplant to others, users' intention to use the method in the future, and service satisfaction were taken into consideration. Uniplant was considered easy to use, safe (low risk of pregnancy), and also to cause fewer side effects than other methods. When asked about the least liked feature of Uniplant, almost half the respondents said that there was nothing that they disliked and about one-third mentioned the changes in their menstrual pattern. However, according to the clinical trial, over half of the Uniplant users have bleeding patterns similar to untreated cycles. The majority of respondents did not feel any discomfort during the procedure of insertion and removal of the implant. About 70% of patients in the study stated that they required contraception for more than one year and most of these women said that they did not mind having to change the implant every year.
authors.affiliation: Maternidade Climério de Oliveira, Federal University of Bahia, Salvador, Brazil.
authors.forename: E M
authors.initials: EM
authors.lastname: Coutinho
authors.forename: C
authors.initials: C
authors.lastname: Athayde
authors.forename: I
authors.initials: I
authors.lastname: Barbosa
authors.forename: F
authors.initials: F
authors.lastname: Alvarez
authors.forename: V
authors.initials: V
authors.lastname: Brache
authors.forename: Z P
authors.initials: ZP
authors.lastname: Gu
authors.forename: E E
authors.initials: EE
authors.lastname: Emuveyan
authors.forename: A O
authors.initials: AO
authors.lastname: Adekunle
authors.forename: L
authors.initials: L
authors.lastname: Devoto
authors.forename: O M
authors.initials: OM
authors.lastname: de Acosta
authors.forename: J
authors.initials: J
authors.lastname: Mati
authors.forename: O A
authors.initials: OA
authors.lastname: Ladipo
mesh_terms: D000328:Adult; D004343:Drug Implants; D005260:Female; D006801:Humans; D007407:Interviews as Topic; D008535:Megestrol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D017060:Patient Satisfaction / Q000706:statistics & numerical data; D045167:Progesterone Congeners / Q000008:administration & dosage / Q000009:adverse effects; D011795:Surveys and Questionnaires
chemical_list: D004343:Drug Implants; D045167:Progesterone Congeners; C047637:nomegestrol; D008535:Megestrol